
USD
+$0.00
(+0.00%
)At Close (As of Dec 9, 2025)
$554.83M
Market Cap
-
P/E Ratio
-0.45
EPS
$3.07
52 Week High
$0.35
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $24M |
| Total Revenue | $25M |
| Cost Of Revenue | $1.6M |
| Costof Goods And Services Sold | $1.6M |
| Operating Income | -$177M |
| Selling General And Administrative | $63M |
| Research And Development | $137M |
| Operating Expenses | $201M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $3.1M |
| Income Before Tax | -$170M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$170M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$177M |
| Ebitda | -$174M |
| Net Income | -$170M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $24M |
| Total Revenue | $25M |
| Cost Of Revenue | $1.6M |
| Costof Goods And Services Sold | $1.6M |
| Operating Income | -$177M |
| Selling General And Administrative | $63M |
| Research And Development | $137M |
| Operating Expenses | $201M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $3.1M |
| Income Before Tax | -$170M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$170M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$177M |
| Ebitda | -$174M |
| Net Income | -$170M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Invivyd Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the discovery and development of advanced antibody-based therapies to combat infectious diseases. The company leverages its proprietary technologies and extensive immunology expertise to address critical unmet medical needs, highlighted by a promising pipeline of innovative therapeutic solutions. By focusing on the development of targeted antibody therapies, Invivyd positions itself at the forefront of biopharmaceutical advancements, aiming to enhance patient outcomes and respond effectively to global health challenges.